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Abstract: The calcium-sensing receptor (CaSR) is the main regulator of extracellular Ca2+ homeostasis.
It has diverse functions in different tissues, including the intestines. Intestine-specific knockout of
the CaSR renders mice more susceptible to dextran sulphate sodium (DSS)-induced colitis. To test
our hypothesis that the CaSR reduces intestinal inflammation, we assessed the effects of nutritional
and pharmacological agonists of the CaSR in a colitis model. We treated female Balb/C mice with
dietary calcium and protein (nutritional agonists of the CaSR) or pharmacological CaSR modulators
(the agonists cinacalcet and GSK3004774, and the antagonist NPS-2143; 10 mg/kg), then induced
colitis with DSS. The high-protein diet had a strong pro-inflammatory effect—it shortened the colons
(5.3 ± 0.1 cm vs. 6.1 ± 0.2 cm normal diet, p < 0.05), lowered mucin expression and upregulated
pro-inflammatory cytokines, such as interferon-γ, (4.2-fold, p < 0.05) compared with the normal
diet. Cinacalcet reduced mucin expression, which coincided with an increase in tumor necrosis
factor-α (4.4-fold, p < 0.05) and IL-6 (4.9-fold, p < 0.05) in the plasma, compared with vehicle.
The CaSR antagonist, NPS-2143, significantly reduced the cumulative inflammation score compared
with the vehicle control (35.3 ± 19.1 vs. 21.9 ± 14.3 area under the curve, p < 0.05) and reduced
infiltration of inflammatory cells. While dietary modulation of the CaSR had no beneficial effects,
pharmacological inhibition of the CaSR may have the potential of a novel add-on therapy in the
treatment of inflammatory bowel diseases.
Keywords: IBD; colitis; inflammation; calcium; mucin
1. Introduction
The calcium-sensing receptor (CaSR) is a dimeric G protein-coupled receptor (GPCR) that plays
a central role in calcium homeostasis. The CaSR is expressed at highest levels in the parathyroid
glands and kidneys, where it regulates parathyroid hormone release and calcium reabsorption [1,2].
What distinguishes the CaSR from other members of the GPCR family is its sensitivity to minute
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alterations in extracellular Ca2+ over the millimolar range, which enables it to function as the body’s
calciostat [3]. Besides extracellular Ca2+, the CaSR responds to numerous ligands including divalent
and trivalent cations, polyamines, amino acids, antibiotics and other external stimuli such as pH
and ionic strength [4]. At the cellular level, the CaSR fine-tunes numerous signaling pathways
downstream of Gi, GQ/11, G12/13 and β-arrestin in a ligand- and tissue-dependent manner [5–10]. This is
evident in the diversity of the physiological processes that the CaSR regulates, spanning calcitropic
and non-calcitropic tissues, i.e., those not directly involved in calcium homeostasis. These include
proliferation, differentiation, hormone secretion and excitability to name but a few [1]. There is
increasing interest in the role of the CaSR in non-calcitropic tissues including the gastrointestinal tract
(GI), where the CaSR has been suggested to function as a nutrient sensor and to regulate intestinal
motility, fluid transport and inflammation [11–15]. Accordingly, the CaSR may potentially be a
therapeutic target for toxin-mediated diarrhea and intestinal inflammation.
There exists a reciprocal relationship between the CaSR and inflammation. Inflammatory cytokines
(tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1β) and IL-6) regulate the transcription of the CaSR,
while the CaSR itself broadly regulates inflammation in a tissue-dependent manner (see reference [11]
for a full review). For example, in the lung, the CaSR has pro-inflammatory effects and thus offers a
therapeutic potential for CaSR antagonists to treat asthma [16]. Conversely, previous studies suggested
a protective role for the CaSR in intestinal inflammation, which highlights the CaSR as a promising
target for inflammatory bowel disease (IBD) treatment [17–19]. IBD encompasses Crohn’s disease,
which affects the entire gastrointestinal tract, and ulcerative colitis, which only affects the colon. There is
no cure for either disease. Animal models for IBD, such as the dextran sulphate sodium (DSS)-induced
colitis model, are widely used in preclinical drug development [20]. Intake of DSS in drinking water
either acutely or chronically results in symptoms that are reminiscent of colitis.
Initial findings linking the CaSR to intestinal inflammation come from a study on DSS-induced
colitis by Cheng et al., where knockout of the CaSR in intestinal epithelia increased susceptibility to
DSS [17]. Loss of the CaSR in intestinal epithelia compromised the epithelial barrier, thus leading
to infiltration by pathogens and immune cells and an imbalance in gut immunity, favoring
inflammation [17]. It was also reported that high dietary calcium intake reduces intestinal inflammation
and the associated risk for colorectal cancer [21,22]. The luminal CaSR along the GI tract is available
to modulation by a plethora of ligands including divalent cations, amino acids, polyamines and
glutamyl dipeptides as products of food intake and digestion. Therefore, the CaSR might represent
a druggable target that is favorable for nutraceutical supplementation, as well as pharmaceutical
intervention for treating IBD. Two independent studies by Zhang et al. demonstrated that amino acids
and glutamyl dipeptides alleviate DSS-induced colitis symptoms in vivo and inhibit TNF-α-induced
pro-inflammatory cytokine production in vitro [19,23]. More recently, Liu et al. also suggested that CaSR
activation by aromatic amino acids mitigates intestinal inflammation in lipopolysaccharide-challenged
piglets [24]. Despite the evidence presented in these studies, they have two major limitations. First,
CaSR dependence is not adequately demonstrated, particularly in vitro where the cell lines used are
reported to have little or no CaSR expression [25]. Second, although the ligands that were used are
known agonists or allosteric modulators of the CaSR, they are not highly selective. Furthermore, to our
knowledge, there are no reports on the effects of positive allosteric modulators (calcimimetics) such as,
cinacalcet or NPS-R568, on intestinal inflammation.
To address these limitations, we have chosen two approaches to study the putative involvement
of the CaSR in intestinal inflammation. First, we have used diets containing different levels of the
main CaSR ligand, Ca2+, in addition to a high protein diet which is a major source of amino acids
and peptides. Second, we used highly selective pharmacological CaSR ligands to target the luminal
CaSR in the intestines and hypothesized that modulating the CaSR will influence DSS-induced colitis
in mice. For a combined local and systemic effect, we used the clinically available calcimimetic
cinacalcet (Sensipar/Mimpara). For a more localized effect and to achieve high drug concentrations in
the intestines, we used - for the first time - a gut-restricted calcimimetic (GSK3004744) [26]. We also
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used the calcilytic NPS-2413 to inhibit the CaSR. We found that dietary protein exacerbated acute
DSS-induced colitis. Moreover, we showed for the first time that cinacalcet had pro-inflammatory
effects highlighted by a reduction in mucin and an increase in pro-inflammatory cytokines in the
plasma. On the contrary, NPS-2143 alleviated clinical symptoms of colitis. Our study uncovered
previously unknown effects of allosteric modulators of the CaSR on acute intestinal inflammation.
2. Materials and Methods
2.1. Mouse Handling and Maintenance
All animal experiments were approved by the Ethics Committee of the Medical University of Vienna
and the Austrian Federal Ministry of Education, Science and Research (BMWFW-66.009/0401-WF/V/3b/)
and carried out in accordance with the European Union Regulations on Care and Use of Laboratory
Animals. Female BALB/c mice (8 weeks, 16−20 g; Charles River Laboratories, Inc., Sulzfeld/Grabfeld,
Germany) were group housed on a 12 h−12 h light−dark cycle and allowed unrestricted access to
the standard semi-synthetic diet AIN-93M (LASCRdiet™ LasVendi, Germany), which contained 0.5%
calcium and 13% protein, or the experimental diets as indicated. All experimental diets were isocaloric
and differed from the standard (control) diet only in calcium and protein content as follows: low
calcium (0.05%), high calcium (1.5%) and high protein (26%). The amounts of dietary calcium and
protein are listed in Table 1. The full composition of the diets is listed in Table S1.
Table 1. Protein and calcium content in the standard semi-synthetic diet (LASCRdiet™ LasVendi).
Ingredients Amount (g/kg Diet)
Normal Ca2+ Low Ca2+ High Ca2+ High Protein
Casein (> or =85% protein) 140.000 140.000 140.000 260.000
Supplemental CaCO3 12.495 0.000 37.485 12.495
2.2. Experimental Design and Induction of Colitis
The optimal concentration of DSS for induction of inflammation in BALB/c mice was determined in
a pilot study. We tested 2.5, 3 and 3.5% DSS and determined that clear clinical symptoms were observed
with 3.5% DSS. Thus, 3.5% DSS was given in drinking water ad libitum for 7 days followed by a short
3-day resolution phase. “No-DSS” control mice received normal drinking water. Two independent
studies were carried out to determine the effects of dietary and pharmacological modulators of the
CaSR on DSS colitis. In the diet study, the mice were randomly assigned into groups (10/group)
and were fed ad libitum one of the following diets: normal calcium (0.5%), low calcium (0.05%),
high calcium (1.5%) and high protein (26% protein). The mice were fed with the experimental diets
for 3 weeks prior to DSS administration and continued until the end of the experiment (Figure 1A).
For assessment of the effects of the allosteric modulators of the CaSR on DSS colitis, the mice were
randomly assigned into groups (25/group) and received by oral gavage: cinacalcet (Tocris Bioscience,
Bristol, UK), GSK3004744, or NPS-2143 (Tocris Bioscience, Bristol, UK) at 10 mg/Kg body weight,
dissolved in 20% (2-hydroxypropyl)-β-cyclodextrin (Sigma Aldrich) in distilled water. Vehicle treated
mice received 20% cyclodextrin only. Gavage, administered on weekdays, lasted for 2 weeks, beginning
1 week prior to the DSS treatment and until the day of euthanasia (Figure 1B). Animals were euthanized
3 days post-DSS or upon reaching the criteria for a humane endpoint (clinical score = 16, see next
section). Blood was collected by heart puncture, centrifuged at 2000× g for 5 min and plasma was
collected in tubes coated with lithium heparin and stored at −80 ◦C. Colons were removed from
cecum to anus, flushed with PBS and their lengths and weights were measured. Colons were cut
longitudinally; one half was rolled in a Swiss roll, fixed in 4% Roti-Histofix (Roth, Germany) and
paraffin embedded for histological analysis. The remaining half was divided into right and left and
snap frozen for protein extraction.
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Figure 1. Schematic representation of the experimental design. Colitis was induced by dextran 
sulphate sodium (DSS) (3.5%) in drinking water for 7 days, followed by a 3-day resolution phase. (a) 
Mice received semi-synthetic diets (based on AIN-93M) differing in calcium and protein content as 
follows: normal calcium (0.5%), low calcium (0.05%), high calcium (1.5%) and high protein (26%), 
throughout the course of the experiment. (b) Mice received a daily dose (10 mg/Kg) of either vehicle 
(20% cyclodextrin) or calcium-sensing receptor (CaSR) allosteric modulators (NPS-2143, GSK3004774 
or cinacalcet) by gavage; treatments started 7 days prior to DSS administration and continued until 
euthanasia. 
2.3. Clinical Assessment of Colitis 
Mice were weighed and monitored weekly prior to DSS and gavage treatment. Throughout the 
DSS course, mice were monitored daily and scored for physical symptoms of colitis, under blinded 
conditions, according to the criteria by Chassing et al. [27] as follows. Physical appearance: 0 = 
normal, 1 = general lack of grooming, 2 = staring coat, ocular and nasal discharges, 4 = piloerection, 
hunched up. Body weight loss: 0 = normal 1 = 5–10%, 2 = 10–15%, 4 = > 15%. Behavior: 0 = normal, 1 = 
mild depression or exaggerated response, 2 = less mobile and alert, isolated, 4 = vocalization, 
self-mutilation, restless, violence, inactive, cold. Feces: 0 = normal, 1 = soft, positive fecal occult blood 
test, Haemoccult (Beckman Coulter), 2 = very soft with visible traces of blood, 4 = visible rectal 
bleeding. If no stool could be collected on one day, the average score of the adjacent former and 
latter days was used, or, in case of no possibility of further scoring, the score was continued to the 
end of the experiment. 
2.4. Histology Scoring 
Colon sections were processed as per standard histology protocol, formalin-fixed, embedded in 
paraffin and sliced into 4 µm sections. The sections were stained by hematoxylin and eosin and 
Images were acquired using TissueFAXS Hard and Software (TissueGnostics GmbH, Wien, 
Austria), using a 20x Objective (Neo-Fluar NA 0.5; Zeiss, Oberkochen, Germany). Scoring was 
carried out by an experienced pathologist under blinded conditions, and was based on evaluation of 
inflammation, ulceration, mucosal remodeling and number of lymph follicles. 
2.5. Mucin quantification 
In order to determine the amount of mucin per epithelium, paraffin-embedded colon sections 
were stained by alcian blue for mucin and nuclear fast red and images were acquired using 
TissueFAXS Hard- and Software, using a 20× Objective (Neo-Fluar NA 0.5). Images were then 
downsized and converted to 8–bit images for analysis with Image J [28]. In order to quantify the total 
area of epithelium per section accurately, we excluded lymph follicles and staining artefacts using 
manual segmentation of the images. The muscularis layer was automatically segmented using the 
trainable Waikato environment for image analysis (WEKA) [29]. We then used color deconvolution 
[30] and thresholding to separate and quantify the mucin positive area per area of epithelium. 
Figure 1. Sche atic representation of the experimental design. Colitis was induced by dextran sulphate
sodium (DSS) (3.5%) in drinking water for 7 days, followed by a 3-day resolution phase. (a) Mice
received semi-synthetic diets (based on AIN-93M) differing in calcium and protein content as follows:
normal calcium (0.5%), low calcium (0.05%), high calcium (1.5%) and high protein (26%), throughout the
course of the experiment. (b) Mice received a daily dose (10 mg/Kg) of either vehicle (20% cyclodextrin)
or calcium-sensing receptor (CaSR) allosteric modulators (NPS-2143, GSK3004774 or cinacalcet) by
gavage; treatments started 7 days prior to DSS administration and continued until euthanasia.
2.3. Clinical Assessment of Colitis
Mice were weighed and monitored weekly prior to DSS and gavage treatment. Throughout the
DSS course, mice were monitored daily and scored for physical symptoms of colitis, under blinded
conditions, according to the criteria by Chassing et al. [27] as follows. Physical appearance: 0 = normal,
1 = general lack of grooming, 2 = staring coat, ocular and nasal discharges, 4 = piloerection, hunched
up. Body weight loss: 0 = normal 1 = 5–10%, 2 = 10–15%, 4 = > 15%. Behavior: 0 = normal, 1 = mild
depression or exaggerated response, 2 = less mobile and alert, isolated, 4 = vocalization, self-mutilation,
restless, violence, inactive, cold. Feces: 0 = normal, 1 = soft, positive fecal occult blood test, Haemoccult
(Beckman Coulter), 2 = very soft with visible traces of blood, 4 = visible rectal bleeding. If no stool
could be collected on one day, the average score of the adjacent former and latter days was used, or, in
case of no possibility of further scoring, the score was continued to the end of the experiment.
2.4. Histology Scoring
Colon sections were processed as per standard histology protocol, formalin-fixed, embedded
in paraffin and sliced into 4 µm sections. The sections were stained by hematoxylin and eosin and
Images were acquired using TissueFAXS Hard and Software (TissueGnostics GmbH, Wien, Austria),
using a 20x Objective (Neo-Fluar NA 0.5; Zeiss, Oberkochen, Germany). Scoring was carried out by
an experienced pathologist under blinded conditions, and was based on evaluation of inflammation,
ulceration, mucosal remodeling and number of lymph follicles.
2.5. Mucin Qu tification
In order to determine the amount of mucin per epithelium, paraffin-embedded colon sections were
stained by alcian blue for mucin and nuclear fast red and images were acquired using TissueFAXS Hard-
and Software, using a 20× Objective (Neo-Fluar NA 0.5). Images were then downsized and converted
to 8–bit images for analysis with Image J [28]. In order to quantify the total area of epithelium per
section accurately, we excluded lymph follicles and staining artefacts using manual segmentation of the
images. The muscularis layer was automatically segmented using the trainable Waikato environment
for image analysis (WEKA) [29]. We then used color deconvolution [30] and thresholding to separate
and quantify the mucin positive area per area of epitheliu .
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2.6. Cytokine Multiplex Assay
The 36-Plex Mouse ProcartaPlex Panel 1A (Thermo Fisher Scientific, Waltham, MA, USA) was
used to quantify chemokines and cytokines from plasma and colon extracts as per the manufacturer’s
instructions. Briefly, a minimum of 2 plasma samples from each group were pooled and 25 µL per
pool was used in duplicates. Frozen right and left colon pieces were lysed in ProcartaPlex lysis buffer
containing protease inhibitor (1:500) and phenylmethylsulfonyl fluoride (PMSF; 1 mM) in an automatic
homogenizer (Precellys, Germany) at 6500 rpm for 10 seconds. Protein was then quantified by the BCA
method, pooled with a minimum of 2 samples per pool and 250 µg per pool were loaded in duplicates.
2.7. Immunohistochemistry
Paraffin-embedded colon sections were incubated for 25 min at 60 ◦C, deparaffinized,
and rehydrated. After washing with PBS (pH 7.2), sections were boiled in 0.05% citrate buffer
for antigen retrieval, permeabilized with 0.2% Tween-20 in PBS for 20 min, and blocked with 5%
goat serum in PBS for 30 min. Sections were simultaneously incubated with rabbit monoclonal
anti-β-catenin antibody (Abcam, Cambrige, UK; 1:100) and rat monoclonal anti-Ki-67 antibody-eFluor
570 (eBioscience; 1:250) overnight at 4 ◦C, followed by extensive washing with PBS and incubation
with secondary antibody: goat anti-rabbit-AlexaFluor 647 (1:2000). To detect immune cell infiltration,
sections were incubated with rabbit anti-mouse cluster of differentiation T cell co-receptor 3 (CD3)
(Abcam; 1:100) and mouse anti-mouse CD20 (Santa Cruz, CA, USA, 1:100) overnight at 4 ◦C, followed by
extensive washing with PBS and incubation with secondary antibody: goat anti-rabbit-AlexaFluor 647
(1:2000). Rabbit and mouse IgG were used as negative controls. Nuclei were stained with DAPI (1:1000)
for 10 min at room temperature and samples were mounted using Fluoromount-G. Whole section
images were acquired with the automated TissueFAXS system (TissueGnostics GmbH, Wien, Austria).
2.8. Quantification of Immune Cell Infiltration
CD3+ and CD20+ cells were analyzed under blinded conditions in whole Swiss roll sections by
TissueQuest Software (TissueGnostics GmbH, Wien, Austria) using nuclear segmentation based on
nuclear DAPI staining, with nuclear and ring masks for the respective target protein to encompass
the whole cell. Manual thresholding for positive cells was used for each target and then applied to
all tissue sections. The analysis was performed separately for lymph nodes (marked manually) and
extra-lymphatic tissue for CD3+ and CD20+ cells.
2.9. GSK3004774 Synthesis
GSK3004774 was synthesized according to literature procedures [26,31] and obtained as a 99%
pure, 1:2 diastereomeric mixture of 1-(3-(4-((S)-3-(((R)-1-(naphthalen-1-yl)ethyl)amino)pyrrolidin-1-
yl)benzamido)propyl)piperidine-4-carboxylic acid and 1-(3-(4-((R)-3-(((R)-1-(naphthalen-1-yl)ethyl)
amino)pyrrolidin-1-yl)benzamido)propyl)piperidine-4-carboxylic acid).
2.10. Intracellular Ca2+ Measurements to Test the Activity of GSK3004774
Techniques using the ratiometric Ca2+ indicator fura-2 AM have been previously described [16].
In brief, HEK293 cells stably transfected with the human CaSR (HEK-CaSR; a kind gift from Professor
Daniela Riccardi, Cardiff University) and grown on 13 mm glass coverslips coated in poly-D-lysine
were loaded with Fura-2 AM (Thermo Fisher) for 2 hours at 37 ◦C. After washing, the cells were
pre-incubated in extracellular solution (135 mM NaCl, 10 mM glucose, 5 mM KCl, 5 mM HEPES,
1.2 mM MgCl2) containing 0.2 mM Ca2+ and either vehicle (0.1% v/v DMSO) or 1 µM GSK3004774 for
10 min. Fluorescence of Fura-2 was then recorded at 340 and 380 nm using an inverted fluorescence
microscope (IX71, Olympus. Shinjuku, Tokyo, Japan) at 2 second intervals. A rapid perfusion system
allowed changing of the solutions. Fluorescence was recorded for 2 min at 0.2 mM Ca2+ (baseline),
followed by 3 min at 3 mM Ca2+, followed again by 2 min at 2 mM Ca2+. Integrated response units
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(IRUs: trapezoidal integral of the timespan) were calculated of the baseline and the last two minutes
of the 3 mM Ca2+ phase and the value for baseline was subtracted from the value for the 3 mM Ca2+
phase (∆IRU). An increase in the intracellular Ca2+ response (increase in ∆IRU) in the GSK3004774
treated cells compared to vehicle treatment indicated a stronger activation of the CaSR and thus activity
of the compound GSK3004774 as a calcimimetic (Figure S1a–d).
2.11. Statistical Analysis
Data are presented as the mean ± SEM or median ± interquartile range. Statistical analyses were
carried out using GraphPad Prism version 7.0 (GraphPad, San Diego, CA, USA). Used statistical tests
are indicated with the respective figures or tables.
3. Results
3.1. Clinical Symptoms of Colitis were Exacerbated by High Dietary Protein, but Improved by NPS-2143
During the acclimatization period and prior to colitis induction, we monitored body weight
and determined that the different diets and the allosteric modulators had no influence on body
weight (Figure S2a,b).
To determine the effects of dietary calcium and protein on colitis symptoms, we divided the mice
into four groups and fed them the following diets: normal calcium (0.5%) and protein, low calcium,
high calcium, and high protein (Table 1). DSS induced minor weight loss and a significant shortening of
colons compared with the no-DSS control group (Figure 2a). The high protein diet caused a significant
loss of weight compared with the normal diet group in colitic mice (Figure S2c). The colons of mice fed
with the high protein diet were significantly shorter than those of the normal diet group (5.3 ± 0.11 and
6.1 ± 0.20 cm, p = 0.0102) (Figure 2a). The deleterious effects of the high protein diet were also reflected
in the clinical score, which was highest in the high protein diet group (Figure 2c,e).
The high calcium diet had no effect on the clinical score during the induction phase. However,
there was a small but not statistically significant reduction in the clinical score during the resolution
phase (Figure 2c). The low calcium diet had no effect on clinical score compared with the normal diet
group. One mouse died due to severe inflammation in the high protein diet group as shown in the
survival curve (Figure S3a).
It is suggested that activation of the CaSR in the intestines attenuates DSS-induced colitis [18,19].
Therefore, we examined the effects of pharmacological CaSR modulators: two positive allosteric
modulators, cinacalcet and GSK3004774, and the negative allosteric modulator NPS-2143. We tested
the effectiveness of the allosteric modulators by measuring serum parathyroid hormone (PTH)
levels. As expected, NPS-2143 increased, cinacalcet caused a statistically insignificant reduction,
while GSK3004774 had no effect on PTH levels (Figure S4). All the DSS-treated groups which received
either 20% cyclodextrin only as a vehicle or 10 mg/Kg of allosteric modulators experienced substantial
weight loss (Figure S2d). This is likely a result of gavage which increased the inflammatory response,
as reflected in the clinical score and pro-inflammatory cytokine expression in the plasma and in the
left colon (Figure S5a–d). However, we observed no differences in the weight loss (Figure S2d) or
colon length (Figure 2b) among the different treatment groups throughout the induction and resolution
phases. Neither cinacalcet, nor GSK3004774 affected the clinical score. By contrast, NPS-2143 reduced
the clinical score in the resolution phase (Figure 2d). We analyzed the cumulative score (area under
the curve) for the clinical score (Figure 2f), which was significantly lower for the NPS-2143 group
(21.9 ± 14.3) compared with the vehicle group (35.3 ± 19.1, p < 0.05). During colitis induction, several
spontaneous fatalities were observed during the daily assessment and mice that reached the humane
threshold (clinical score > 15) had to be euthanized. Interestingly, most mice survived in the group
treated with NPS-2143 (88%), compared with vehicle- (64%), cinacalcet- (60%) and GSK3004774- (72%)
treated groups (Figure S3b).
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cumulative clinical score of colitic mice fed with different diets (e) or treated with CaSR allosteric 
modulators (f). Statistical significance was determined by one-way ANOVA or Kruskal–Wallis for 
ranked clinical scores. *p < 0.05, **p < 0.01 and ***p < 0.001 were regarded as statistically significant. 
Data are presented as the mean ± SEM, n = 10 and 25 mice per group, for the diets and modulators 
experiments, respectively. 
3.2. Histological Scores were Increased by High Dietary Protein, while Unaffected by Dietary Calcium and The 
Pharmacological Modulators of The CaSR. 
DSS profoundly affected colon histology (Figure 3a). Histology score in the DSS model 
represents a key parameter in preclinical drug studies. The high protein diet caused increased tissue 
damage, which manifested as significantly higher inflammation, ulceration ad mucosal remodeling, 
compared with the normal/standard diet (Figure 3b, d and f). Neither the Ca2+ content (Figure 3b, d 
and f) nor any of the allosteric modulators (Figure 3c, e and g) affected the studied histological 
parameters. Moreover, Ki67 and β-catenin levels were not affected by any of the diets or the 
allosteric modulators of the CaSR (Figure S6 a–d). 
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a d clinical score of colitis. Col n lengths of colitic mice and no-DSS co trols fed with different iets (a)
or treated with CaSR allosteric modulators (b). Clinical score of colitic mice fed with different diets (c) or
treated with CaSR allosteric mo ulators (d) Clinical score is based on (1) ge er l appearance, (2) weight
loss, (3) behavior (4) blood in stool. Area under the curve f the cumulativ clinical score of colitic mice
fed with different diets (e) or treated with CaSR allosteric modulators (f). Statistical significance was
determined by one-way ANOVA or Kruskal–Wallis for ranked clinical scores. * p < 0.05, ** p < 0.01 and
*** p < 0.001 were regarded as statistically significant. Data are presente as the mean ± SEM, n = 10
and 25 mice per group, for the diets and modulators experiments, respectively.
3.2. Histological Scores were Increased by High Dietary Protein, while Unaffected by Dietary Calcium and The
Pharmacological Modulators of The CaSR
DSS profoundly ffected colon histology (Figure 3a). Histology score in the DSS model represents
a key parameter in preclinical drug studies. The high protein diet caused increased tissue damage,
which manifested as significantly higher inflammation, ulceration ad mucosal remodeling, compared
with the normal/standard diet (Figure 3b,d,f). Neither the Ca2+ content (Figure 3b,d,f) nor any of
the allosteric modulators (Figure 3c,e,g) affected the studied histological parameters. Moreover,
Ki67 and β-catenin levels were not affected by any of the diets or the allosteric modulators of the
CaSR (Figure S6a–d).
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3.3. Mucin Was Reduced by High Dietary Protein and the Positive Allosteric Modulator Cinacalcet
Mucin plays a major role in the front line of defense as part of the mucous layer in the GI tract [32].
Therefore, we assessed mucin content in the colon as a correlate for chemical barrier integrity and
recovery of crypt architecture. The inflammatory damage caused by the high protein diet coincided
with a significant reduction in mucin (Figure 4c) compared with the normal diet (Figure 4a), probably
due to the destruction of the epithelial layer. The nutritional agonist Ca2+ had no effect on mucin
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content (Figure 4e), while the positive allosteric modulator cinacalcet caused a small yet statistically
significant reduction in mucin content (Figure 4d) compared with the vehicle control (Figure 4b).
Neither NPS-2143 nor GSK3004774 affected mucin content (Figure 4f).
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3.4. Inflammatory Cytokines are Differentially Affected by Nutritional and Pharmacological CaSR Ligands
Inflammatory cytokines are quantitative markers of inflammation in DSS models [33].
We measured a panel of cytokines in the plasma to examine the effects of the diets and allosteric
modulators and to determine the extent of the systemic inflammation. Indeed, the high protein diet
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caused a significant increase in the expression of pro-inflammatory markers in the plasma, compared
with the normal diet, such as TNF-α (5.0-fold, p < 0.05) and IL-1α (13.4-fold, p < 0.05) (Table S2).
Similarly, cinacalcet significantly increased the expression of TNF-α (4.4-fold, p < 0.05), IL-6 (4.9-fold, p
< 0.05) and IL-1α (2.3-fold, p < 0.05) (Table S2).
Next, we examined the effects of dietary calcium and protein, as well as the CaSR allosteric
modulators, on the expression of cytokines in lysates from the right and left colons. In the right colon,
both low and high levels of dietary calcium reduced the expression level of many cytokines, including
IL-1β and IFN-α (Figure 5a). High dietary protein caused an upregulation of Gro-α/KC, MIP1- and
IL-17, while it caused a downregulation of IL-22 (Table S3). In the left colon, we observed a robust
upregulation of most cytokines by DSS (Table S4). Both high dietary calcium and protein increased the
expression of several cytokines (Table S4). These included IL-1β and TNF-α (Figure 5b). Interestingly,
high dietary calcium decreased the expression of the anti-inflammatory cytokine, IL-10, compared
with the normal diet (Figure 5b). By contrast, high dietary protein caused a marked increase in IL-10,
compared with the normal diet (Figure 5b).
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Figure 5. The effects of dietary calcium, dietary protein and CaSR allosteric modulators on inflammatory
cytokines in the colons of colitic mice. Cytokine expression in the left (a) and the right (b) colons of
colitic mice fed with different diets. Cytokine expression in the right (c) and the left (d) colons of colitic
mice treated with CaSR allosteric modulators. Fold change is relative to no-DSS controls. Statistical
significance was determined by one-way ANOVA. * p < 0.05, ** p < 0.01, *** p < 0.001 were regarded as
statistically significant. Data are presented as the mean ± SEM. Samples were pooled with a minimum
of 2 per pool and measured in duplicates. No DSS controls, n = 4. Experimental diet groups, n = 3.
Allosteric modulator groups, n = 6.
The allosteric modulators of the CaSR differentially affected the levels of cytokines in the right
and left colons (Tables S3 and S4). In the right colon, all three modulators increased the expression of
IFN-α (Table S3), whereas NPS-2143 and GSK3004774 increased the expression of IL-10 (Figure 5c).
Moreover, cinacalcet and GSK3004774 reduced the expression of TNF-α and IL-1 α (Figure 5c). In the
Nutrients 2019, 11, 3072 11 of 16
left colon, all three modulators decreased the expression of IFN-α, GM-CSF and IFN-γ (Table S4) but
increased the expression of IL-10 (Figure 5d).
3.5. NPS-2143 Reduced Immune Cell Infiltration into the Colon
We also compared the extent of the infiltration of CD3+ T cells and CD20+ B cells into the colon
among the different dietary and pharmacological treatments. Dietary calcium and protein did not affect
CD20 infiltration (Figure S7). Interestingly, NPS-2143 significantly reduced the infiltration of CD3+
and CD20+ cells into the colon, compared with the vehicle control (Figure 6a,b,e). Neither GSK3004774
nor cinacalcet affected the infiltration of CD3+ or CD20+ cells into the colon (Figure 6b–e).
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Figure 6. NPS-2143 reduces immune cell infiltration into the colon. (a) Representative images of colon
sections stained with DAPI (blue) and cell markers for CD3 or CD20 (green) from colitic mice treated
with vehicle or NPS-2143. White arrows indicate tissue infiltration, while red arrows indicate ly ph
node infiltration. Images were acquired with TissueFAXS and the percentage of CD3+ and CD20+ cells
per tissue section was quantified using TissueQuest. CD3+ cell infiltration into tissue (b) and lymph
nodes (c) in colitic mice treated with the allosteric modulators of the CaSR. CD20+ cell infiltration into
tissue (d) and lymph node (e) in colitic mice treated with the allosteric modulators of the CaSR. Data are
presented as the mean ± SEM. Statistical significance was determined by Kruskal–Wallis test. * p < 0.05,
** p < 0.01 and *** p < 0.001 were regarded as statistically significant. (Vehicle, n = 10), (NPS-2143, n =
11), (GSK3004774, n = 12), (cinacalcet, n = 9).
4. Discussion
O r findings revealed that dietary calcium and protein differentially affect key parameters in the
DSS colitis mouse model. Supplemental calcium was associated with reduced chronic colitis symptoms
in DSS-treated mice [34]. However, we found no effects of dietary calcium on acute inflammation in our
model, as none of the studied parameters were affected by the calcium content in the diet. It is plausible
that the protective effects of calcium, which were reported to influence epithelial barrier integrity, are
obsolete in the acute DSS model, where epithelial destruction occurs to a large extent and at a very
early stage of the disease. It is noteworthy that basal and inducible levels of most of the analyzed
cytokines were significantly higher in the left colon, which is the segment that is mostly examined in
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DSS models. In our study, dietary calcium increased the expression of several cytokines in the left
colon, e.g., IL-1β. This was perhaps due to the chemoattractant effect of calcium on monocytes [35].
Amino acids and peptides resulting from protein breakdown in the gut may act as agonists
for the luminal CaSR in the intestines [24] and thereby influence disease activity. In our model,
however, we found that high dietary protein exacerbated colitis symptoms, which agrees with
previous studies [36–38]. This confirms that a high protein diet, while potentially modulating
the CaSR, has a deleterious effect on colitis on its own. In light of the results with the positive
pharmacological modulators, it seems implausible that these effects of the high protein diet are actually
CaSR related. The exact mechanism by which high dietary protein exerts such negative effects is
unknown. Several studies showed that dietary content affects microbiota composition, which in turn
influences the severity of inflammation [38]. Amino acid-derived metabolites, such as ammonia,
p-cresol and hydrogen sulfide were shown to impact the epithelium negatively and increase intestinal
permeability [37]. Additionally, it was reported that extraintestinal mechanisms might be involved in
DSS colitis models. For instance, excess nitrogenous supply to the kidneys may worsen the systemic
inflammation by impairing renal functions [39]. Moreover, DSS-induced liver inflammation was
influenced by dietary parameters [40]. Lan et al. showed that high protein content facilitated recovery
from colitis in the resolution phase [36]. However, we did not detect any improvement in the clinical
score during the short 3-day resolution phase.
Our results also suggest that the allosteric modulators of the CaSR differentially influence
key parameters in the DSS-induced colitis mouse model. Contrary to previous reports [19,23],
we found that the negative allosteric modulator NPS-2143 ameliorated the clinical symptoms of
colitis leading to a lower clinical score compared with vehicle and reduced the infiltration of immune
cells. The anti-inflammatory effects of NPS-2143 were already described in lung tissue, where it
alleviated allergen-induced asthma and airway hyperresponsiveness in rodents [16]. The observed
anti-inflammatory effects of NPS-2143 may be mediated partly by inhibition of the CaSR in circulating
immune cells [41,42]. It is also plausible that NPS-2143 may have dual effects depending on the route
of administration. Our study is the first to use oral administration of CaSR allosteric modulators in
pre-clinical colitis models.
The positive allosteric modulators cinacalcet and GSK3004774 had no effect on clinical score,
colon length or histology score. We only detected a reduction in mucin abundance in the mice treated
with cinacalcet. Concomitantly, pro-inflammatory markers in the plasma, such as, TNF-α, IL-6 and
IL1α were increased by cinacalcet, but not by the gut-restricted GSK3004774. This suggests a systemic
effect of cinacalcet, which was lacking in the non-absorbable calcimimetic GSK3004774. Conversely,
in the colons, both calcimimetics decreased the expression of pro-inflammatory markers such as
IL-1α and IFN-γ. This may be explained by the tissue-specific effects of cinacalcet. In the plasma,
CaSR activation in circulating monocytes was associated with activation of the inflammasome [42].
However, these effects may differ in the local environment of the gut. None of the diets or the allosteric
modulators of the CaSR affected proliferation or epithelial integrity of colonocytes, as shown in the
Ki67 and β-catenin levels (Figure S6a–d). As opposed to cinacalcet, GSK3004774, which would only act
on the apical CaSR in the colonocytes, did not affect mucin abundance, suggesting that the deleterious
effects of cinacalcet may be mediated systemically, e.g., through the activation of the basolateral
intestinal CaSR that is exposed to circulating drugs. To date, there are no pre-clinical reports on
the effects of cinacalcet, or other CaSR positive allosteric modulators, on intestinal inflammation.
Nonetheless, one of the adverse side effects of cinacalcet is upper GI bleeding. Although the underlying
mechanism is unknown, it is possible that this arises as a result of CaSR activation in gastric cells [43].
Our extensive cytokine analysis revealed higher basal and DSS-inducible cytokine expression in the left
colon compared with the right colon. The allosteric modulators differentially affected the expression
of several cytokines. However, most of the effects, such as the downregulation of IFN-α and IFN-γ,
do not support CaSR dependence, as the effect was caused by both the agonist, cinacalcet, and the
antagonist, NPS-2143. It is thus possible that these result from off-target effects.
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Taken all the parameters into consideration, our data suggests that inhibiting the CaSR with orally
administered calcilytics may alleviate colitis symptoms. Moreover, our data show for the first time that
orally administered positive allosteric modulators of the CaSR do not alleviate clinical symptoms of
colitis. Moreover, cinacalcet reduced mucin abundance and increased TNF-α, IL-6 and IL1α in the
plasma, suggesting a systemic pro-inflammatory effect. Our interpretation of these findings considers
the limitations of the acute DSS model. First, the short period of resolution may not capture the full
extent of recovery. Therefore, our findings need to be extended into the chronic model, with a lower
DSS concentration and a longer resolution phase. Second, daily administration of drugs via oral gavage
exposes mice to stress and therefore aggravates inflammation. Although necessary for the acute model,
it can be replaced by less frequent administration in the chronic model. Finally, the effects of NPS-2143
will require further testing.
5. Conclusion
The novel findings of this study show that selective calcimimetics are associated largely with
systemic pro-inflammatory effects, without improving the symptoms of DSS-induced colitis. On the
other hand, calcilytics may be beneficial in reducing symptoms of colitis. These results highlight
unprecedented roles of the CaSR in intestinal inflammation and merit further investigation.
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